Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for Fourth Quarter and Full Year Ended Dec. 31, 2013
For the year, the company reported license revenues of $5,000,000, net loss before income taxes of $10,649,000, net loss of $11,149,000 or $1.39 per basic and diluted share, net cash used in operating activities of $13,206,000, purchases of property and equipment of $3,000 compared to the net loss before income taxes of $21,194,000, net loss of $21,194,000 or $6.94 per basic and diluted share, net cash used in operating activities of $18,836,000, purchases of property and equipment of $26,000 for the previous year.